Special Issue

Advanced Research in Chronic Respiratory Diseases (CRDs)

Message from the Guest Editor

Chronic respiratory diseases (CRDs) mainly affect the airways and other lung structures. Most common CRDs are chronic obstructive pulmonary disease (COPD), lung fibrosis, bronchiectasis asthma, occupational lung diseases, and pneumoconiosis. These diseases can be caused by long-term exposure to tobacco smoke or irritating gases; other risk factors include air pollution, occupational chemicals, dust, and frequent lower respiratory infections during childhood. Identifying biomarkers, including inflammatory, image, genomics, microbiome, and molecular endotypes, holds potential to guide individualized therapies for CRD. This Special Issue aims to publish research related to various biomarkers of CRD. This Special Issue will publish full research articles, comprehensive reviews, and shorter perspective articles on all aspects related to the theme of chronic respiratory diseases. Research areas may include (but are not limited to) the following: inflammatory, image, genomics, microbiome, and molecular biomarkers. We look forward to receiving your contributions.

Guest Editor

Dr. Hung-Yu Huang Chang Gung Memorial Hospital, Taipei, Taiwan

Deadline for manuscript submissions

closed (31 May 2025)



an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed



mdpi.com/si/224330

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +4161 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines





an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed





About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access iournal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

- Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
- 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).